Though antineoplastic drugs have demonstrated benefits as a cancer treatment, they pose significant occupational health risks to clinicians administering the drugs. The Centers for Disease Control and ...

Handling antineoplastic agents presents a well-recognised occupational risk owing to their inherent cytotoxicity, mutagenicity and teratogenicity. Healthcare workers may be exposed through dermal ...

Dr. Bradley Hunter, MD, MPH and Ms. Amy Evers, BSN, RN, OCN, MBA join us on the latest episode of the ASCO Guidelines Podcast to share key points and insights on the updated ASCO-ONS antineoplastic ...

Medications are designed to treat diseased tissues while sparing healthy ones, often by attaching the drug to something that helps guide it directly to its target. But drugs also need time to work, ...

According to the National Brain Tumor Society, approximately 1.3 million Americans are living with a brain tumor. The ...

An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies. An emerging class of anticancer drugs called EZH2 inhibitors may greatly ...

Research by UMass Chan Medical School scientists Sharon Cantor, Ph.D., and Jenna M. Whalen, Ph.D., poses a new explanation for how cancer-fighting drugs attack and destroy BRCA1 and BRCA2 tumor cells.

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

Cancer cells frequently develop the ability to expel anticancer drugs before they can work -- a phenomenon called multidrug ...

Domestic new drugs, which used to be released once or twice a year, have already received approval for two this year by April ...